Skip to Main Content

Imagine inhaling a sensor that could monitor lung disease patients’ response to therapy, emitting a signal when they breathe out. Like a breathalyzer that recognizes alcohol, such a device could sniff out compounds released only by specific illnesses to gauge how well treatment is working.

Biomedical engineers at the Massachusetts Institute of Technology have developed a synthetic biosensor using specialized nanoparticles to detect and then report the presence of molecules indicating bacterial pneumonia or the genetic disease alpha-1 antitrypsin deficiency. 

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!